CARsgen Therapeutics is a clinical-stage immune-oncology company that develops a new chimeric T-cell antigen receptor. It offers therapeutics that help liver, lung, stomach and brain cancers treatment. The company has established several in-house platforms including antibody discovery, lentiviral vector production and next-generation CAR-T cell technologies.
|Employees (est.) (Sept 2021)||65||(+9%)|
CARsgen Therapeutics total Funding
CARsgen Therapeutics latest funding size
Time since last funding
|a year ago|
CARsgen Therapeutics investors
|KTB Ventures, JIC GenesisFountain Healthcare Ventures, Jolly Innovation Ventures, Kaitai Capital, Lilly Asia Ventures, Loyal Valley Capital, Photon Fund, Shiyu Capital, Summer Capital, BVCV, South China Venture Capital|
CARsgen Therapeutics has 73 Twitter Followers. The number of followers has increased 21.3% month over month and increased 44.7% quarter over quarter
When was CARsgen Therapeutics founded?
CARsgen Therapeutics was founded in 2014.
Who are CARsgen Therapeutics key executives?
CARsgen Therapeutics's key executives are Zonghai Li, Li Zonghai and Huamao Wang.
How many employees does CARsgen Therapeutics have?
CARsgen Therapeutics has 72 employees.
Who are CARsgen Therapeutics competitors?
Competitors of CARsgen Therapeutics include LIPAC Oncology, OncoQuest and Bexion Pharmaceuticals.
Where is CARsgen Therapeutics headquarters?
CARsgen Therapeutics headquarters is located at 1F, Building 2, NO, 466 Yindu Rd, Minhang Qu, Shanghai.
Where are CARsgen Therapeutics offices?
CARsgen Therapeutics has offices in Shanghai, Beijing and Bellaire.
How many offices does CARsgen Therapeutics have?
CARsgen Therapeutics has 5 offices.
Receive alerts for 300+ data fields across thousands of companies